巩膜外手术联合玻璃体内植入0.7毫克地塞米松治疗具有增殖性玻璃体视网膜病变高风险的孔源性视网膜脱离
Rhegmatogenous Retinal Detachment with a High Risk of Proliferative Vitreoretinopathy Treated with Episcleral Surgery and an Intravitreal Dexamethasone 0.7-mg Implant.
作者信息
Reibaldi Michele, Russo Andrea, Longo Antonio, Bonfiglio Vincenza, Uva Maurizio G, Gagliano Caterina, Toro Mario D, Avitabile Teresio
机构信息
Department of Ophthalmology, University of Catania, Catania, Italy.
出版信息
Case Rep Ophthalmol. 2013 Apr 24;4(1):79-83. doi: 10.1159/000351176. Print 2013 Jan.
PURPOSE
To report a case of rhegmatogenous retinal detachment with a high risk of proliferative vitreoretinopathy (PVR) effectively treated with episcleral surgery and an intravitreal dexamethasone 0.7-mg implant.
METHODS
A 35-year-old Caucasian man with a macula-off rhegmatogenous subtotal retinal detachment that had persisted for 1 month in his myopic left eye presented several risk factors that could have led to the development of PVR after retinal detachment surgery. His best corrected visual acuity was hand motion. He received an intravitreal dexamethasone 0.7-mg implant (Ozurdex(®)) after episcleral surgery to prevent this complication.
RESULTS
At least 9 months after surgery, no sign of PVR or pucker has developed in the treated eye. Visual acuity improved to 0.2, the retina was attached and no complications were observed.
CONCLUSION
Intravitreal dexamethasone 0.7-mg implant (Ozurdex) could be considered as off-label treatment following episcleral surgery to prevent PVR.
目的
报告1例孔源性视网膜脱离且具有增殖性玻璃体视网膜病变（PVR）高风险的患者，经巩膜外手术联合玻璃体内注射0.7毫克地塞米松植入剂治疗有效。
方法
一名35岁的白种男性，其左眼近视，黄斑脱离的孔源性视网膜脱离部分持续1个月，存在视网膜脱离手术后可能导致PVR发生的多个风险因素。其最佳矫正视力为手动。在巩膜外手术后，他接受了玻璃体内注射0.7毫克地塞米松植入剂（Ozurdex®）以预防该并发症。
结果
术后至少9个月，患眼未出现PVR或视网膜前膜迹象。视力提高到0.2，视网膜复位，未观察到并发症。
结论
玻璃体内注射0.7毫克地塞米松植入剂（Ozurdex）可被视为巩膜外手术后预防PVR的超说明书用药治疗。
Zotero 插件